Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child

References

• Shen K, Yu H, Xie B, et al. Anticancer or carcinogenic? The role of estrogen receptor β in breast cancer progression. Pharmacol Therapeut. 2023;242:1–16. doi: 10.1016/j.pharmthera.2023.108350
   Web of Science ®Google Scholar
• Hwang NM, Stabile LP. Estrogen receptor ß in cancer: to ß(e) or not to ß(e)? Endocrinology. 2021;162(11):1–12. doi: 10.1210/endocr/bqab162
   Web of Science ®Google Scholar
• Hawkins RA, White G, Bundred NJ, et al. Prognostic significance of oestrogen and progestogen receptor activities in breast cancer. Br J Surg. 1987;74(11):1009–1013. doi: 10.1002/bjs.1800741118
   PubMed Web of Science ®Google Scholar
• NCCN. National comprehensive cancer network clinical practice guidelines in oncology (NCCN Guidelines) breast cancer. Version 3.2023– March 3, 2023
   Google Scholar
• Leo CP, Leo C, Szucs TD. Breast cancer drug approvals by the US FDA from 1949 to 2018. Nat Rev Drug Discov. 2020;19(1):11. doi: 10.1038/d41573-019-00201-w
   PubMed Web of Science ®Google Scholar
• Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–1846. doi: 10.1056/NEJMoa1701830
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Wardell SE. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr Opin Pharmacol. 2010;10(6):620–628. doi: 10.1016/j.coph.2010.09.007
   PubMed Web of Science ®Google Scholar
• Oesterreich S, Davidson NE. The search for ESR1 mutations in breast cancer. Nat Genet. 2013;45(12):1415–1416. doi: 10.1038/ng.2831
   PubMed Web of Science ®Google Scholar
• Glück S. Extending the clinical benefit of endocrine therapy for women with hormone receptor–positive metastatic breast cancer: differentiating mechanisms of action. Clin Breast Cancer. 2014;14(2):75–84. doi: 10.1016/j.clbc.2013.10.008
   PubMed Web of Science ®Google Scholar
• Wardell SE, Ellis MJ, Alley HM, et al. Efficacy of SERD/SERM hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy–resistant breast cancer. Clin Cancer Res. 2015;21(22):5121–5130. doi: 10.1158/1078-0432.CCR-15-0360
   PubMed Web of Science ®Google Scholar
• Bihani T, Patel HK, Arlt H, et al. Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER(+) breast cancer patient-derived xenograft models. Clin Cancer Res. 2017;23(16):4793–4804. doi: 10.1158/1078-0432.CCR-16-2561
   PubMed Web of Science ®Google Scholar
• Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–4600. doi: 10.1200/JCO.2010.28.8415
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62(1):233–247. doi: 10.1146/annurev-med-070909-182917
   PubMedGoogle Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2- negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439. doi: 10.1016/S1470-2045(15)00613-0
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Ettl J, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 2016;18(1):67. doi: 10.1186/s13058-016-0721-5
   PubMed Web of Science ®Google Scholar
• Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA -mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940. doi: 10.1056/NEJMoa1813904
   PubMed Web of Science ®Google Scholar
• Mittal A, Valiente CM, Tamimi F, et al. Filling the gap after CDK4/6 inhibitors: novel endocrine and biologic treatment options for metastatic hormone receptor positive breast cancer. Cancers (Basel). 2023;15(7):1–20. doi: 10.3390/cancers15072015
   Web of Science ®Google Scholar
• Chandarlapaty S, Chen D, He W, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. 2016;2(10):1310–1315. doi: 10.1001/jamaoncol.2016.1279
   PubMed Web of Science ®Google Scholar
• Fanning SW, Mayne CG, Dharmarajan V, et al. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife. 2016;5. doi: 10.7554/eLife.12792
   PubMedGoogle Scholar
• Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor–positive advanced breast cancer. J Clin Oncol. 2016;34(25):2961–2968. doi: 10.1200/JCO.2016.67.3061
   PubMed Web of Science ®Google Scholar
• Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439–1445. doi: 10.1038/ng.2822
   PubMed Web of Science ®Google Scholar
• Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer. Clin Cancer Res. 2014;20(7):1757–1767. doi: 10.1158/1078-0432.CCR-13-2332
   PubMed Web of Science ®Google Scholar
• Li S, Shen D, Shao J, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4(6):1116–1130. doi: 10.1016/j.celrep.2013.08.022
   PubMed Web of Science ®Google Scholar
• Jeselsohn R, Buchwalter G, De Angelis C, et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12(10):573–583. doi: 10.1038/nrclinonc.2015.117
   PubMed Web of Science ®Google Scholar
• van Kruchten M, de Vries EG, Glaudemans AW, et al. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. Cancer Discov. 2015;5(1):72–81. doi: 10.1158/2159-8290.CD-14-0697
   PubMed Web of Science ®Google Scholar
• Lloyd MR, Wander SA, Hamilton E, et al. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone-receptor positive breast cancer: current and emerging role. Ther Adv Med Oncol. 2022;14:1–25.
   Web of Science ®Google Scholar
• Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2023 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02653417
   Google Scholar
• Wardell SE, Nelson ER, Chao CA, et al. Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. Endocr Relat Cancer. 2015;22(5):713–724. doi: 10.1530/ERC-15-0287
   PubMed Web of Science ®Google Scholar
• Garner F, Shomali M, Paquin D, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015;26(9):948–956. doi: 10.1097/CAD.0000000000000271
   PubMed Web of Science ®Google Scholar
• Patel HK, Tao N, Lee KM, et al. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. Breast Cancer Res. 2019;21(1):146. doi: 10.1186/s13058-019-1230-0
   PubMed Web of Science ®Google Scholar
• Varella L, Cristofanilli M. Evaluating elacestrant in the management of ER-positive, HER2-negative advanced breast cancer: evidence to date. Onco Targets Ther. 2023;16:189–196.
   PubMed Web of Science ®Google Scholar
• Bardia A, Kaklamani V, Wilks S, et al. Phase I study of elacestrant (RAD1901), a novel selective estrogen receptor degrader, in ER-positive, HER2-negative advanced breast cancer. J Clin Oncol. 2021;39(12):1360–1370. doi: 10.1200/JCO.20.02272
   PubMed Web of Science ®Google Scholar
• Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40(28):3246–3256. doi: 10.1200/JCO.22.00338
   PubMed Web of Science ®Google Scholar
• Bardia A, Bidard FC, Neven P, et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting. Presented at: San Antonio Breast Cancer Symposium (SABCS) 2022; 2022 Dec; San Antonio (TX). Abstract G3-01
   Google Scholar
• FDA.gov [Internet]. Silver Spring (MD): U.S. Food and Drug Administration. [cited 2023 May 26]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer
   Google Scholar
• Medford AJ, Leshchiner I, Cha J, et al. ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2023. 2023 Jun; Chicago (IL). Abstract 1074
   Google Scholar
• Rugo H, Bardia A, Cortés J, et al. ELEVATE: a phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC). Presented at: San Antonio Breast Cancer Symposium (SABCS) 2023. 2023 Dec; San Antonio (TX). Abstract PO2-05-04
   Google Scholar
• Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2023 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT05386108
   Google Scholar
• Tolaney SM, Sahebjam S, Le Rhun E, et al. A phase II study of Abemaciclib in patients with brain metastases secondary to hormone receptor–positive breast cancer. Clin Cancer Res. 2020;26(20):5310–5319. doi: 10.1158/1078-0432.CCR-20-1764
   PubMed Web of Science ®Google Scholar
• Hernando C, Oretga-Morillo B, Tapia M, et al. Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Int J Mol Sci. 2021;22(15):1–21. doi: 10.3390/ijms22157812
   Web of Science ®Google Scholar
• Bardia A, Chandarlapaty S, Linden HM, et al. AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. Nat Commun. 2022;13(1):4116. doi: 10.1038/s41467-022-31668-8
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Chan A, Petrakova K, et al. AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC). Presented at: european Society for Medical Oncology (ESMO) 2022. Paris, France; 2022 Sep. Abstract LBA14.
   Google Scholar
• Martin Jimenez M, Lim E, Gregor M C-M, et al. Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): primary analysis of the phase II, randomised, open-label acelERA BC study. Ann Oncol. 2022;33(suppl_7):S88–S121. doi: 10.1016/j.annonc.2022.07.250
   Google Scholar
• Oliveira M, Pominchuk D, Nowecki Z, et al. Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: results of the randomized, multi-dose phase 2 SERENA-2 trial. Presented at: San Antonio Breast Cancer Symposium (SABCS) 2022. 2022 Dec; San Antonio (TX). Abstract GS3-02
   Google Scholar
• Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2023 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04964934
   Google Scholar
• Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2023 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04961996
   Google Scholar
• Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2023 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT05514054
   Google Scholar
• Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2024 Jan 21]. Available from: https://www.clinicaltrials.gov/study/NCT04436744
   Google Scholar
• Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/study/NCT05306340
   Google Scholar
• Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/study/NCT04576455
   Google Scholar
• Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/study/NCT04546009
   Google Scholar
• Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/study/NCT04975308
   Google Scholar
• Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/study/NCT05774951
   Google Scholar
• Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2024 Jan 21]. Available from: https://www.clinicaltrials.gov/study/NCT05952557?term=cambria-2&rank=1
   Google Scholar
• Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2024 Jan 21]. Available from: https://www.clinicaltrials.gov/study/NCT04711252
   Google Scholar
• Jin X, Zhou Y, Ma D, et al. Molecular classification of hormone-receptor positive HER2-negative breast cancer. Nat Genet. 2023;55(10):1696–1708. doi: 10.1038/s41588-023-01507-7
   PubMed Web of Science ®Google Scholar